ES2860527T3 - Método y aparato para determinar una tasa de filtración de un paciente - Google Patents
Método y aparato para determinar una tasa de filtración de un paciente Download PDFInfo
- Publication number
- ES2860527T3 ES2860527T3 ES16712833T ES16712833T ES2860527T3 ES 2860527 T3 ES2860527 T3 ES 2860527T3 ES 16712833 T ES16712833 T ES 16712833T ES 16712833 T ES16712833 T ES 16712833T ES 2860527 T3 ES2860527 T3 ES 2860527T3
- Authority
- ES
- Spain
- Prior art keywords
- patient
- creatinine
- filtration rate
- glomerular filtration
- determining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 91
- 238000001914 filtration Methods 0.000 title description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 254
- 229940109239 creatinine Drugs 0.000 claims abstract description 127
- 230000024924 glomerular filtration Effects 0.000 claims abstract description 47
- 210000002966 serum Anatomy 0.000 claims abstract description 47
- 238000012959 renal replacement therapy Methods 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 230000004584 weight gain Effects 0.000 claims abstract description 16
- 235000019786 weight gain Nutrition 0.000 claims abstract description 16
- 210000004369 blood Anatomy 0.000 claims abstract description 13
- 239000008280 blood Substances 0.000 claims abstract description 13
- 238000005259 measurement Methods 0.000 claims description 44
- 210000000476 body water Anatomy 0.000 claims description 18
- 238000012545 processing Methods 0.000 claims description 10
- 239000002934 diuretic Substances 0.000 claims description 8
- 230000001882 diuretic effect Effects 0.000 claims description 8
- 238000004590 computer program Methods 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 description 31
- 238000004088 simulation Methods 0.000 description 17
- 238000001631 haemodialysis Methods 0.000 description 12
- 230000000322 hemodialysis Effects 0.000 description 12
- 238000007796 conventional method Methods 0.000 description 11
- 238000000502 dialysis Methods 0.000 description 11
- 208000020832 chronic kidney disease Diseases 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000011277 treatment modality Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 201000000523 end stage renal failure Diseases 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000010989 Bland-Altman Methods 0.000 description 2
- 206010016803 Fluid overload Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000011863 diuretic therapy Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000885 nephron Anatomy 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 241000243251 Hydra Species 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000012733 comparative method Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
- A61B5/0531—Measuring skin impedance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
- A61B5/0537—Measuring body composition by impedance, e.g. tissue hydration or fat content
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Radiology & Medical Imaging (AREA)
- Medical Informatics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15160600 | 2015-03-24 | ||
| PCT/EP2016/056545 WO2016151087A1 (en) | 2015-03-24 | 2016-03-24 | Method and apparatus for determining a patient's filtration rate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2860527T3 true ES2860527T3 (es) | 2021-10-05 |
Family
ID=52807600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16712833T Active ES2860527T3 (es) | 2015-03-24 | 2016-03-24 | Método y aparato para determinar una tasa de filtración de un paciente |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11079397B2 (enExample) |
| EP (1) | EP3274723B1 (enExample) |
| JP (1) | JP6857608B2 (enExample) |
| CN (1) | CN107533070A (enExample) |
| ES (1) | ES2860527T3 (enExample) |
| WO (1) | WO2016151087A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3671753A1 (en) | 2018-12-19 | 2020-06-24 | Fresenius Medical Care Deutschland GmbH | Dialysis treatment modalities; method and devices |
| CN110738927B (zh) * | 2019-10-29 | 2024-05-28 | 中南大学湘雅医院 | 一种多功能高灵敏度肾小球滤过率显示器 |
| CN116325017A (zh) * | 2020-10-05 | 2023-06-23 | 甘布罗伦迪亚股份公司 | 估计残余肾功能 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5280429A (en) | 1991-04-30 | 1994-01-18 | Xitron Technologies | Method and apparatus for displaying multi-frequency bio-impedance |
| US5865763A (en) * | 1996-08-13 | 1999-02-02 | St. Luke's-Roosevelt Hospital | Method for estimating creatinine clearance in obese and malnourished subjects using measurements of body cell mass |
| JP3901827B2 (ja) * | 1998-01-30 | 2007-04-04 | 新里 徹 | 血液透析データを用いたクレアチニン産生速度の算定方法 |
| CN1960672B (zh) | 2004-06-29 | 2010-05-12 | 弗雷森纽斯医疗护理德国有限责任公司 | 确定病人水合和/或营养状况的方法和装置 |
| WO2006123253A2 (en) | 2005-03-29 | 2006-11-23 | Inverness Medical Switzerland Gmbh | Device and method of monitoring a patient |
| AU2007320718A1 (en) * | 2006-11-14 | 2008-05-22 | Flowsense Ltd | A diagnostic method and apparatus |
-
2016
- 2016-03-24 JP JP2017549731A patent/JP6857608B2/ja not_active Expired - Fee Related
- 2016-03-24 CN CN201680017609.7A patent/CN107533070A/zh active Pending
- 2016-03-24 US US15/558,224 patent/US11079397B2/en not_active Expired - Fee Related
- 2016-03-24 WO PCT/EP2016/056545 patent/WO2016151087A1/en not_active Ceased
- 2016-03-24 EP EP16712833.9A patent/EP3274723B1/en not_active Not-in-force
- 2016-03-24 ES ES16712833T patent/ES2860527T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11079397B2 (en) | 2021-08-03 |
| JP6857608B2 (ja) | 2021-04-14 |
| EP3274723B1 (en) | 2021-01-13 |
| CN107533070A (zh) | 2018-01-02 |
| EP3274723A1 (en) | 2018-01-31 |
| JP2018511053A (ja) | 2018-04-19 |
| HK1243487A1 (zh) | 2018-07-13 |
| WO2016151087A1 (en) | 2016-09-29 |
| US20180080947A1 (en) | 2018-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pottel et al. | Estimating glomerular filtration rate at the transition from pediatric to adult care | |
| Lindner et al. | Hypernatremia in the critically ill is an independent risk factor for mortality | |
| Filler et al. | Educational review: measurement of GFR in special populations | |
| Lewis et al. | Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate | |
| Hou et al. | Comparison of different assessments for evaluating malnutrition in Chinese patients with end-stage renal disease with maintenance hemodialysis | |
| Berend | Acid–base pathophysiology after 130 years: confusing, irrational and controversial | |
| Friedman et al. | Measuring the glomerular filtration rate in obese individuals without overt kidney disease | |
| Li et al. | Medullary blood oxygen level-dependent MRI index (R2*) is associated with annual loss of kidney function in moderate CKD | |
| Thanakitcharu et al. | Early detection of subclinical edema in chronic kidney disease patients by bioelectrical impedance analysis | |
| CN106456865A (zh) | 使用血液稀释的绝对血量估计 | |
| Saylor et al. | Prenatal blood lead levels and reduced preadolescent glomerular filtration rate: Modification by body mass index | |
| CN102481102B (zh) | 用于估计表示病人身体内存在的物质的质量或浓度的值的方法和装置 | |
| Rodenbach et al. | Renal response to a protein load in healthy young adults as determined by iohexol infusion clearance, cimetidine-inhibited creatinine clearance, and cystatin C estimated glomerular filtration rate | |
| Vega et al. | Study on overhydration in dialysis patients and its association with inflammation | |
| Wybrańczyk et al. | Glucose management indicator–potential factors affecting differences in comparison with HbA1c and clinical significance of this phenomenon | |
| JP6857608B2 (ja) | 患者の濾過量を算定する方法および器械 | |
| Bernales-Delmon et al. | Oral creatine in hemodialysis patients increases physical functional capacity and muscle mass, an open label study | |
| Jani et al. | Cerebral oxygenation and perfusion when positioning preterm infants: clinical implications | |
| Wu et al. | Reevaluation of the protein requirement in Chinese elderly adults without sarcopenia with the indicator amino acid oxidation technique | |
| Wang et al. | Association of age to nutritional status and muscle mass in children with transfusion-dependent β-thalassemia: a cross-sectional study | |
| Kellum | Making strong ion difference the" Euro" for bedside acid-base analysis | |
| Sen et al. | Total body water and fat-free mass: evaluation of equations based on bioelectrical impedance analysis in infants and young children in India | |
| Zhang et al. | Femoral venous oxygen saturation and central venous oxygen saturation in critically ill patients | |
| Mokarami | Pitfalls in interpreting umbilical cord blood gases and lactate at birth | |
| Kulkarni et al. | Improvement in estimates of GFR by using fat-free mass as compared to body weight in Indians: pilot study |